Search research articles
Contact Us
Filters
Showing results (261-270 of 362) with videos related to
Page
of 37
Sort By:
Lung Cancer (Amsterdam, Netherlands)
|
September 20, 2021
Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trials
Solange Peters, Sarah Danson, Dunson Ejedepang, et al.
ERJ Open Research
|
June 24, 2026
Immunotherapy-related interstitial lung disease: a call to improve risk stratification and diagnostic consistency
Laura Fabbri, Katerina Antoniou, Torsten Gerriet Blum, et al.
Lancet (London, England)
|
August 16, 2015
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
Miklos Pless, Roger Stupp, Hans-Beat Ris, et al.
Cancer Cell
|
October 22, 2020
Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERAVOLT Experience
Annalisa Trama, Claudia Proto, Jennifer G Whisenant, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 29, 2025
First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With <i>EGFR</i> Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial
Pasi A Jänne, Bin-Chao Wang, Byoung Chul Cho, et al.
Nature Medicine
|
June 19, 2024
Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial
Solange Peters, Shirish M Gadgeel, Tony Mok, et al.
Journal for Immunotherapy of Cancer
|
October 25, 2023
PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma
Krisztian Homicsko, Panagiota Zygoura, Maxim Norkin, et al.
Lung Cancer (Amsterdam, Netherlands)
|
August 7, 2025
Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial
Anne-Marie C Dingemans, Konstantinos Syrigos, Lorenzo Livi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2026
First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6-Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non-Small Cell Lung Cancer
Solange Peters, Sarina A Piha-Paul, Kartik Sehgal, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
November 20, 2019
Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays' and cross-validation with resections, in patients with, stage I-III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort
Erik Thunnissen, Keith M Kerr, Urania Dafni, et al.
Page
of 37
Search research articles
Search
Showing results (261-270 of 362) with videos related to
Sort By:
Page
of 37
Lung Cancer (Amsterdam, Netherlands)
|
September 20, 2021
Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trials
Solange Peters, Sarah Danson, Dunson Ejedepang, et al.
ERJ Open Research
|
June 24, 2026
Immunotherapy-related interstitial lung disease: a call to improve risk stratification and diagnostic consistency
Laura Fabbri, Katerina Antoniou, Torsten Gerriet Blum, et al.
Lancet (London, England)
|
August 16, 2015
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
Miklos Pless, Roger Stupp, Hans-Beat Ris, et al.
Cancer Cell
|
October 22, 2020
Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERAVOLT Experience
Annalisa Trama, Claudia Proto, Jennifer G Whisenant, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 29, 2025
First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With <i>EGFR</i> Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial
Pasi A Jänne, Bin-Chao Wang, Byoung Chul Cho, et al.
Nature Medicine
|
June 19, 2024
Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial
Solange Peters, Shirish M Gadgeel, Tony Mok, et al.
Journal for Immunotherapy of Cancer
|
October 25, 2023
PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma
Krisztian Homicsko, Panagiota Zygoura, Maxim Norkin, et al.
Lung Cancer (Amsterdam, Netherlands)
|
August 7, 2025
Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial
Anne-Marie C Dingemans, Konstantinos Syrigos, Lorenzo Livi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2026
First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6-Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non-Small Cell Lung Cancer
Solange Peters, Sarina A Piha-Paul, Kartik Sehgal, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
November 20, 2019
Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays' and cross-validation with resections, in patients with, stage I-III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort
Erik Thunnissen, Keith M Kerr, Urania Dafni, et al.
Page
of 37